Atara Biotherapeutics (NASDAQ:ATRA) Cut to Hold at RODMAN&RENSHAW

RODMAN&RENSHAW downgraded shares of Atara Biotherapeutics (NASDAQ:ATRA) from a strong-buy rating to a hold rating in a research report released on Tuesday morning,Zacks.com reports.

A number of other brokerages have also weighed in on ATRA. Canaccord Genuity Group decreased their price target on shares of Atara Biotherapeutics from $21.00 to $17.00 and set a “buy” rating on the stock in a report on Friday, January 17th. Rodman & Renshaw started coverage on Atara Biotherapeutics in a research report on Friday, December 20th. They set a “buy” rating and a $25.00 price target for the company. TD Cowen upgraded Atara Biotherapeutics to a “strong-buy” rating in a report on Friday, November 29th. Finally, HC Wainwright reiterated a “neutral” rating on shares of Atara Biotherapeutics in a report on Wednesday. One research analyst has rated the stock with a sell rating, three have issued a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $17.75.

Atara Biotherapeutics Trading Up 13.9 %

Atara Biotherapeutics stock opened at $6.89 on Tuesday. The stock has a fifty day moving average price of $12.16 and a 200 day moving average price of $9.97. Atara Biotherapeutics has a 52 week low of $5.40 and a 52 week high of $39.50. The firm has a market capitalization of $39.69 million, a P/E ratio of -0.27 and a beta of 0.51.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, topping the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million for the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter in the previous year, the company earned ($16.50) earnings per share. As a group, equities analysts predict that Atara Biotherapeutics will post -9.86 EPS for the current year.

Institutional Investors Weigh In On Atara Biotherapeutics

Several institutional investors and hedge funds have recently modified their holdings of ATRA. Geode Capital Management LLC raised its holdings in shares of Atara Biotherapeutics by 9.5% during the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock valued at $380,000 after buying an additional 4,043 shares during the period. State Street Corp grew its position in Atara Biotherapeutics by 52.3% in the third quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after acquiring an additional 7,680 shares in the last quarter. FMR LLC raised its stake in shares of Atara Biotherapeutics by 41.7% during the third quarter. FMR LLC now owns 25,061 shares of the biotechnology company’s stock valued at $204,000 after purchasing an additional 7,381 shares during the period. Cubist Systematic Strategies LLC acquired a new position in shares of Atara Biotherapeutics during the second quarter worth $79,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Atara Biotherapeutics in the second quarter valued at $53,000. Hedge funds and other institutional investors own 70.90% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.